---
title: "BTIG Sticks to Their Buy Rating for Tempus AI, Inc. Class A (TEM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285843315.md"
description: "BTIG analyst Mark Massaro has maintained a Buy rating for Tempus AI, Inc. Class A (TEM) with a price target of $80.00, while the stock closed at $49.86. The analyst consensus is a Moderate Buy with an average price target of $69.23, indicating a potential upside of 38.85%. TD Cowen also supports a Buy rating with a $68.00 target."
datetime: "2026-05-10T13:38:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285843315.md)
  - [en](https://longbridge.com/en/news/285843315.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285843315.md)
---

# BTIG Sticks to Their Buy Rating for Tempus AI, Inc. Class A (TEM)

BTIG analyst Mark Massaro reiterated a Buy rating on Tempus AI, Inc. Class A on May 8 and set a price target of $80.00. The company’s shares closed last Friday at $49.86.

### Claim 55% Off TipRanks

Forget margin or options. Here's how the pros trade TEM

According to TipRanks, Massaro is an analyst with an average return of \-4.7% and a 31.91% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Cerus, SOPHiA GENETICS, and NeoGenomics.

Currently, the analyst consensus on Tempus AI, Inc. Class A is a Moderate Buy with an average price target of $69.23, which is a 38.85% upside from current levels. In a report released on May 6, TD Cowen also maintained a Buy rating on the stock with a $68.00 price target.

### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)
- [SOPH.US](https://longbridge.com/en/quote/SOPH.US.md)
- [NEO.US](https://longbridge.com/en/quote/NEO.US.md)

## Related News & Research

- [How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here](https://longbridge.com/en/news/286786866.md)
- [Tempus AI Prices $460 Million 0% Convertible Notes Due 2032, Retires Senior Credit Facility](https://longbridge.com/en/news/286239704.md)
- [Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts](https://longbridge.com/en/news/286453944.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)